AbCellera Biologics (ABCL) Stock

NASDAQ / Healthcare / Biotechnology

$11.89

+6.78% Close Nov 6

ABCL stock daily candlestick chart with 50, 150 and 200-day moving averagesOpen interactive chart
One year of daily prices through the Nov 6, 2026 close. This page updates by about 4 AM ET after each trading day. The interactive chart has the full history.

ABCL stock price and performance

ABCL stock closed at $11.89 on Nov 6, 2026. The tables below use that final daily session.

Last close
$11.89
Day range
$11.20 to $11.98
52-week range
$2.75 to $15.02
From 52-week high
−20.9%
Average volume (50 days)
4.4M
1 week
−3.1%
1 month
−1.1%
3 months
+27.3%
Year to date
+247.5%
1 year
+153.4%
3 years
+188.5%
5 years
−24.4%

Is ABCL stock in an uptrend?

Yes, ABCL stock is in an uptrend: both Daily Pivot Breakout momentum filters are active, although it does not meet the Minervini Trend Template criteria. Price is above its 200-day moving average.

Daily Pivot momentum filters
2 of 2 active
100-day ROC
+133.5% filter at 40%: active
100-day EMA slope
+132.2% filter at 25%: active
Trend state
Uptrend
Minervini Trend Template
Not met on the latest scan
50-day average
Below
150-day average
Above
200-day average
Above
200-day slope (1 month)
+14.04%
ATR (14) % of price
8.33%

Momentum filters from the Daily Pivot Breakout indicator: 100-day rate of change and 100-day EMA slope, each against its minimum.

Is ABCL stock in a Stage 2 uptrend?

Yes, ABCL stock is in a Stage 2 uptrend by our Weinstein stage analysis: its price is above a rising 30-week moving average and it is outperforming SPY.

Weinstein stage
Stage 2 (advancing)
30-week SMA
$8.40
30-week slope (4 weeks)
+15.61%
Mansfield RS vs SPY
86.87
Weeks in Stage 2
22

Weinstein stage analysis uses weekly closes against the 30-week moving average and Mansfield relative strength versus SPY. See the free Stage 2 stocks screener.

ABCL support and resistance levels

LevelPriceFrom close
Daily Pivot resistance (pivot high)$13.86+16.6%
50-day SMA$12.28+3.3%
21-day EMA$12.19+2.6%
9-day EMA$12.00+1.0%
Latest Daily Pivot low$10.32−13.2%
30-week SMA$8.40−29.3%
150-day SMA$8.24−30.7%
200-day SMA$7.04−40.8%

Levels above the close act as resistance, levels below as support. Last close $11.89.

ABCL breakout and scanner signals

ScannerLast signal (free view, 5 sessions late)Past year
VCPNone in the last year0
RSI DivergenceSep 24, 2026 (bearish)2
Weinstein Stage AnalysisOct 30, 2026A more recent signal (last 5 sessions) is in the journal.103
Daily Pivot BreakoutSep 28, 20264
Minervini Trend TemplateOct 29, 202654
Episodic PivotAug 10, 20261
Ichimoku TK crossOct 19, 2026 (bearish)6
9/21 EMA crossOct 28, 2026A more recent signal (last 5 sessions) is in the journal.4
Golden / Death CrossJun 1, 20261
RS RatingOct 30, 2026A more recent signal (last 5 sessions) is in the journal.64

ABCL seasonality by month

  1. Jan+0.3%67% up
  2. Feb−12.0%0% up
  3. Mar−5.9%17% up
  4. Apr−5.6%33% up
  5. May+5.4%67% up
  6. Jun+14.5%50% up
  7. Jul−0.7%50% up
  8. Aug+10.1%50% up
  9. Sep+7.6%67% up
  10. Oct−2.2%50% up
  11. Nov−0.8%60% up
  12. Dec−3.1%20% up

Average monthly return over 6+ years of stored daily closes, and the share of years each month closed higher.

ABCL earnings history

ReportedEPS estimateEPS actualSurprise
Aug 5, 2026$-0.16$-0.18−12.5%
Jul 16, 2026$1.10$1.17+6.4%
May 11, 2026$-0.20$-0.14+30.0%
Feb 24, 2026$-0.18$-0.03+83.3%

ABCL bull and bear case

What looks strong

  • Stage 2 uptrend by our Weinstein stage analysis scanner.
  • Both Daily Pivot momentum filters are active (100-day ROC 133.5%, 100-day EMA slope 132.2%).
  • The 50, 150 and 200-day averages are stacked in uptrend order.
  • Price is above a rising 200-day moving average.
  • Had a Daily Pivot Breakout on 2026-09-28.

What looks weak

  • Does not meet the Minervini Trend Template on the latest scan.
  • Price is below the 50-day moving average.
  • Short interest is 12.16% of shares outstanding.
  • Net income over the last 12 months is negative.

Drawn only from the data on this page. Not a recommendation.

ABCL news and SEC filings, last 30 days

No SEC filings in the last 30 days.

ABCL insider trading and risks

Risk flags from the data

  • Short interest is 12.16% of shares outstanding.
  • Net income over the last 12 months is negative.

Insider trades: SEC Form 4 open-market purchases and sales.

ABCL valuation and fundamentals

Market cap
$3.85B
Enterprise value
$3.36B
P/E (trailing)
-24.3
P/E (forward)
-14.6
PEG
-0.49
Price to sales
54.51
Price to book
3.81
EV to EBITDA
-16.8
Gross margin
–
Operating margin
−1,550.0%
Profit margin
−248.8%
Return on equity
−17.3%
Revenue (TTM)
$66.2M
Revenue growth (quarter, y/y)
−76.3%
Cash
$540.1M
Debt
$135.6M
Beta
1.59
Fiscal yearRevenueNet incomeFree cash flow
2025$75.1M−$146.4M−$131.3M
2024$28.8M−$162.9M−$197.6M
2023$38.0M−$146.4M−$120.8M
2022$485.4M$158.5M$203.6M

ABCL dividends and splits

Dividend yield
0.00%
Payout ratio
0.0%

Who owns ABCL?

Shares outstanding
306.5M
Float
209.0M
Held by insiders
+21.7%
Held by institutions
+36.8%
Short interest (% of shares)
+12.2%
Days to cover
5.7

What does AbCellera Biologics Inc. do?

CEO
Dr. Carl L.G. Hansen Ph.D.
Employees
596
Headquarters
Vancouver, BC, Canada

Updated Nov 6, 2026. Prices and fundamentals: Source: Twelve Data. Filings and insider trades: SEC EDGAR. Charts: TradingView Lightweight Charts. Educational information, not investment advice.